USPTO serial 79397452
GENE COMPANY
Reviewed by CopyMark Law Group
Status 645Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- BIBB, SCOTT
- Law office
- TMEG LAW OFFICE 109
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with GENE COMPANY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michael T. Smith
Michael T. Smith Birch Stewart Kolasch & Birch LLP2600 Park Tower Drive, Suite 600Vienna, VA 22180United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biological, and bacteriological preparations, other than for medical or veterinary use, for scientific and research use, or for the manufacture of pharmaceuticals; chemical, biological, and bacteriological preparations for scientific and research use, or for the manufacture of pharmaceuticals, namely, preparations containing RNA nanoparticle technologies; RNA nanoparticles, namely, RNA packaged lipid nanoparticles, RNA packaged cell derived extracellular vesicles, chemically modified RNAs capable of naked delivery for scientific, laboratory or medical research use | ACTIVE | — |
| 005 | Diagnostic medical, biological, and pharmaceutical preparations for SARS, Flu, MRSA, Dengue, COPD, Idiopathic pulmonary fibrosis, liver failure, liver cancer, NASH, Stroke, Pancreatic cancer, oral squamous cell cancer, Acute myloid leukemia (AML), skin burn, skin scarring, skin aging, eye diseases such as vitreoretinal eye disease, and Macular degeneration, diabetes, obesity for medical laboratory use; vaccines; vaccine adjuvants; DIAGNOSTIC medical, biological, and pharmaceutical preparations for SARS, Flu, MRSA, Dengue, COPD, Idiopathic pulmonary fibrosis, liver failure, liver cancer, NASH, Stroke, Pancreatic cancer, oral squamous cell cancer, Acute myloid leukemia (AML), skin burn, skin scarring, skin aging, eye diseases such as vitreoretinal eye disease, and Macular degeneration, diabetes, obesity for medical use, namely, preparations containing novel RNA nanoparticle technologies; nanoparticle formulations for pharmaceutical, medical or medical diagnostic purposes, namely, RNA packaged lipid and extravesicular nanoparticles; backbone modified conjugated RNAs, drug delivery agents for medical use consisting of RNA nanoparticle formulations that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations comprising drug delivery agents based on RNA nanoparticle formulations; pharmaceutical preparations, namely, RNA and delivery agents comprised of nanoparticle carriers and polymers for the delivery of RNA to human cells | ACTIVE | — |
| 040 | Custom manufacture of pharmaceutical products including manufacture of pharmaceutical preparations containing RNA, nucleic acids, protein nanoparticles; providing information in the field of custom manufacture of pharmaceuticals | ACTIVE | — |
| 042 | Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology, namely, design and testing for new product development; design, engineering, research, and development services in the field of novel RNA nanoparticle technologies for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 7, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 7, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 7, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 30, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Nov 12, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 12, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 31, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 31, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 31, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 19, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 30, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 30, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 26, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 25, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 24, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 20, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 20, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 13, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |